Postoperative Follow-Up Schedule After Total Hip Arthroplasty
For patients with high-quality implants (ODEP 10A minimum) undergoing uncomplicated primary total hip arthroplasty, routine follow-up from 1 to 10 years postoperatively can be safely eliminated, provided rapid access to orthopaedic review is available; however, a clinical and radiological evaluation is recommended at the 10-year mark.* 1
Evidence-Based Follow-Up Framework
Early Postoperative Period (First Year)
- First visit: Most surgeons see patients at approximately 4-6 weeks postoperatively, with 63% of patients evaluated by 6 weeks and an average first visit at 4.9 weeks 2
- Second visit: The majority (90%) of surgeons perform a 1-year follow-up evaluation 2
- This early surveillance period allows assessment of wound healing, early complications, and initial functional recovery
Years 1-10: Risk-Stratified Approach
For Non-Complex Cases with High-Quality Implants:
- No routine follow-up is necessary from years 1-10 if the implant meets ODEP 10A* minimum criteria 1
- This disinvestment in routine surveillance is safe and cost-effective for standard cases 1
- Patients must have rapid access to orthopaedic review if symptoms develop 1
For Complex Cases or Lower-Quality Implants:
- Periodic follow-up may be required throughout the 1-10 year period 1
- Complex cases include patients with individual risk factors or surgical factors that increase failure risk 1
- Implants not meeting ODEP 10A* criteria warrant more frequent surveillance 1
The 10-Year Milestone
- Mandatory clinical and radiological evaluation at 10 years for all patients 1
- This assessment determines the frequency of subsequent follow-up 1
- The 10-year timepoint is emphasized due to lack of robust evidence beyond this period 1
Beyond 10 Years
- Follow-up frequency should be based on findings from the 10-year assessment 1
- Continued rapid access to orthopaedic review remains essential 1
Special Considerations: Metal-on-Metal Implants
For asymptomatic metal-on-metal (MoM) prostheses:
- The FDA recommends routine long-term follow-up every 1-2 years 3
- This includes appropriate radiographs to assess component position, loosening, osteolysis, and signs of adverse reaction to metal debris (ARMD) 3
- MRI surveillance may be beneficial as pseudotumors can develop in asymptomatic patients with MoM implants 3
- Combined ultrasound and MARS-MRI improves diagnostic accuracy for detecting ARMD 3
Important Caveats
Current Practice Variation
- There is substantial variation in follow-up practices with no strong evidence base supporting specific schedules 4
- Existing guidelines are based on expert consensus (level D evidence) rather than clinical studies 4
- The total length of follow-up reported in practice varies from 3 months to indefinite 5
Billing Period Influence
- Clinical practice patterns show a marked increase in follow-up visits immediately after the 90-day global billing period ends (week 14), with a greater than 4-fold increase in visits 6
- This suggests that billing structures may influence follow-up timing more than clinical necessity 6
Limitations of Current Evidence
- Revision surgery cases are not covered by the UK SAFE recommendations 1
- The recommendations apply specifically to primary hip arthroplasty only 1
- Most evidence supporting follow-up schedules is of very low quality 4
Practical Implementation
Key elements for safe implementation of reduced surveillance:
- Establish robust rapid-access pathways for symptomatic patients 1
- Ensure patients understand warning signs requiring urgent evaluation
- Maintain accurate implant registries to identify high-quality versus lower-quality devices 1
- Document baseline radiographs for future comparison 3
The shift toward risk-stratified, evidence-based follow-up represents a departure from traditional routine surveillance, emphasizing quality over quantity of appointments while maintaining safety through accessible care pathways.